组蛋白甲基转移酶 KMT2A：从发育调控到致癌转化。
Histone methyltransferase KMT2A: Developmental regulation to oncogenic transformation.
机构信息
Division of Pediatric Hematology-Oncology, Children's Hospital Los Angeles, Los Angeles, California, USA; Department of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.
Department of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.
出版信息
J Biol Chem. 2024 Oct;300(10):107791. doi: 10.1016/j.jbc.2024.107791. Epub 2024 Sep 18.
Our current understanding of epigenetic regulation is deeply rooted in the founding contributions of Dr C. David Allis. In 2002, Allis and colleagues first characterized the lysine methyltransferase activity of the mammalian KMT2A (MLL1), a paradigm-shifting discovery that brings epigenetic dysregulation into focus for many human diseases that carry KMT2A mutations. This review will discuss the current understanding of the multifaceted roles of KMT2A in development and disease, which has paved the way for innovative and upcoming approaches to cancer therapy.
我们目前对表观遗传调控的理解深深植根于 C. David Allis 博士的开创性贡献。2002 年，Allis 和同事首次表征了哺乳动物 KMT2A（MLL1）的赖氨酸甲基转移酶活性，这一具有开创性的发现使许多携带 KMT2A 突变的人类疾病的表观遗传失调成为焦点。这篇综述将讨论 KMT2A 在发育和疾病中的多方面作用的现有认识，这为癌症治疗的创新和即将出现的方法铺平了道路。
Zotero 插件